CA2232663C - Antagonistes du recepteur d'at1 destines a prevenir et traiter l'insuffisance renale postischemique et a proteger des reins ischemies - Google Patents

Antagonistes du recepteur d'at1 destines a prevenir et traiter l'insuffisance renale postischemique et a proteger des reins ischemies Download PDF

Info

Publication number
CA2232663C
CA2232663C CA002232663A CA2232663A CA2232663C CA 2232663 C CA2232663 C CA 2232663C CA 002232663 A CA002232663 A CA 002232663A CA 2232663 A CA2232663 A CA 2232663A CA 2232663 C CA2232663 C CA 2232663C
Authority
CA
Canada
Prior art keywords
pharmaceutically acceptable
acceptable salt
receptor antagonist
treating
renal failure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002232663A
Other languages
English (en)
Other versions
CA2232663A1 (fr
Inventor
Ulrich Humke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4242452&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2232663(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of CA2232663A1 publication Critical patent/CA2232663A1/fr
Application granted granted Critical
Publication of CA2232663C publication Critical patent/CA2232663C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

On décrit des antagonistes du récepteur d'AT1 et notamment le composé (S)-N-(1-carboxy-2-méthylprop-1-yl)-N-pentanoyl-N-[2'(1H-tétrazol-5-yl)biphényl-4-yl-méthyl]amine (valsartan) de la formule (I), ou un sel de celui-ci, particulièrement un sel de celui-ci acceptable sur le plan pharmacologique. On peut utiliser ces composés pour traiter l'insuffisance rénale postischémique (aiguë ou chronique) et pour protéger le rein ischémié.
CA002232663A 1995-10-06 1996-09-24 Antagonistes du recepteur d'at1 destines a prevenir et traiter l'insuffisance renale postischemique et a proteger des reins ischemies Expired - Fee Related CA2232663C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH2825/95 1995-10-06
CH282595 1995-10-06
PCT/EP1996/004162 WO1997013513A1 (fr) 1995-10-06 1996-09-24 Antagonistes du recepteur d'at1 destines a prevenir et traiter l'insuffisance renale postischemique et a proteger des reins ischemies

Publications (2)

Publication Number Publication Date
CA2232663A1 CA2232663A1 (fr) 1997-04-17
CA2232663C true CA2232663C (fr) 2008-04-08

Family

ID=4242452

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002232663A Expired - Fee Related CA2232663C (fr) 1995-10-06 1996-09-24 Antagonistes du recepteur d'at1 destines a prevenir et traiter l'insuffisance renale postischemique et a proteger des reins ischemies

Country Status (16)

Country Link
US (1) US6071931A (fr)
EP (1) EP0853477B1 (fr)
JP (3) JPH11513395A (fr)
AT (1) ATE225657T1 (fr)
AU (1) AU7213296A (fr)
BR (1) BR9611007A (fr)
CA (1) CA2232663C (fr)
CY (1) CY2428B1 (fr)
DE (1) DE69624253T2 (fr)
DK (1) DK0853477T3 (fr)
ES (1) ES2184892T3 (fr)
MY (1) MY119312A (fr)
PT (1) PT853477E (fr)
TW (1) TW445147B (fr)
WO (1) WO1997013513A1 (fr)
ZA (1) ZA968378B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0855392A3 (fr) 1997-01-22 2000-01-05 Hoechst Aktiengesellschaft Hétérocycles à cinq chaínons contenant des substituants biphénylylsulphoniques, leur procédé de préparation, leur utilisation comme médicament ou agent diagnostique ainsi que médicament les contenant
IT1295405B1 (it) * 1997-09-30 1999-05-12 Merck Sharp & Dohme Italia S P Uso di un antagonista recettoriale di angiotensina ii per la preparazione di farmaci per aumentare il tasso di sopravvivenza di
KR100523112B1 (ko) * 1997-10-17 2005-10-19 유로진 리미티드 레닌-안지오텐신계 억제제의 사용
CN1304000C (zh) 1998-12-23 2007-03-14 诺瓦提斯公司 缬沙坦在制备用于治疗肺癌的药物中的用途
SE9902597D0 (sv) * 1999-07-06 1999-07-06 Astra Ab New use
NZ522953A (en) * 2000-06-22 2005-10-28 Novartis Ag Tablet containing valsartan, microcrystalline cellulose, crospovidone, colloidal anhydrous silica/colloidal silicon dioxide and magnesium stearate
AR032758A1 (es) * 2000-07-19 2003-11-26 Novartis Ag Sales valsartan, un proceso para su fabricacion, composiciones farmaceuticas y el uso de dichas sales para la preparacion de medicamentos
CA2420055C (fr) * 2000-08-25 2010-06-01 Takeda Chemical Industries, Ltd. Agent de reduction du fibrinogene
WO2003089417A1 (fr) * 2002-04-15 2003-10-30 Dr. Reddy's Laboratories Limited Nouvelles formes cristallines de (s)-n-(1-carboxy-2-methyl-prop-1-yl) -n-pentanoyl-n- [2'-(1h-tetrazol-5-yl-)- biphenyl-4-yl methyl] amine (valsartan)
GB0222056D0 (en) * 2002-09-23 2002-10-30 Novartis Ag Process for the manufacture of organic compounds
WO2005097109A1 (fr) * 2004-04-01 2005-10-20 Daniel Batlle Methodes pour obtenir un niveau d'expression d'ace2 protecteur
US10716749B2 (en) * 2005-11-03 2020-07-21 Palo Alto Investors Methods and compositions for treating a renal disease condition in a subject
JP2011063518A (ja) * 2009-09-15 2011-03-31 Tohoku Univ Ａｒｂ及び／又はグリタゾン系血糖降下物質を含有するｏａｔｐ−ｒ遺伝子発現増強組成物
RU2456615C1 (ru) * 2011-03-25 2012-07-20 Федеральное государственное учреждение "Федеральный научный центр трансплантологии и искусственных органов имени академика В.И. Шумакова" Министерства здравоохранения и социального развития Российской Федерации Способ профилактики отторжения трансплантата трупной почки
WO2018002673A1 (fr) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Nouvelles formulations d'antagonistes du récepteur de l'angiotensine ii

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1334092C (fr) * 1986-07-11 1995-01-24 David John Carini Imidazoles bloquant les recepteurs de l'angiotensine ii
DK0403159T3 (da) * 1989-06-14 2000-08-14 Smithkline Beecham Corp Imidazolylalkensyrer
IE70593B1 (en) * 1989-09-29 1996-12-11 Eisai Co Ltd Biphenylmethane derivative the use of it and pharmacological compositions containing same
DE122007000050I1 (de) * 1990-02-19 2007-11-08 Novartis Ag Acylverbindungen
TW201738B (fr) * 1990-03-20 1993-03-11 Sanofi Co
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
IL99246A0 (en) * 1990-09-10 1992-07-15 Abbott Lab Angiotensin ii receptor antagonists and pharmaceutical compositions containing them
SI9210098B (sl) * 1991-02-06 2000-06-30 Dr. Karl Thomae Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo
US5196537A (en) * 1991-03-21 1993-03-23 G. D. Searle & Co. 5-apylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders
GB9110636D0 (en) * 1991-05-16 1991-07-03 Glaxo Group Ltd Chemical compounds
AU675935B2 (en) * 1992-04-13 1997-02-27 Astrazeneca Ab Angiotensin II antagonists against disorders associated withimpaired neuronal conduction velocity, especially diabetic neuropathy
EP0720477A1 (fr) * 1992-09-09 1996-07-10 Vanderbilt University Procede et compositions permettant de maintenir le taux de filtration glomerulaire tout en inhibant l'accumulation de matrices extracellulaires
EP0629408A1 (fr) * 1993-06-16 1994-12-21 LABORATOIRES MERCK, SHARP & DOHME-CHIBRET Combination d'inhibiteurs ACE et d'antagonistes AII

Also Published As

Publication number Publication date
TW445147B (en) 2001-07-11
JPH11513395A (ja) 1999-11-16
DE69624253D1 (de) 2002-11-14
EP0853477A1 (fr) 1998-07-22
JP2011256195A (ja) 2011-12-22
DK0853477T3 (da) 2003-02-10
PT853477E (pt) 2003-01-31
DE69624253T2 (de) 2003-08-07
ATE225657T1 (de) 2002-10-15
US6071931A (en) 2000-06-06
ES2184892T3 (es) 2003-04-16
EP0853477B1 (fr) 2002-10-09
JP2008019273A (ja) 2008-01-31
ZA968378B (en) 1997-04-07
CA2232663A1 (fr) 1997-04-17
MY119312A (en) 2005-05-31
WO1997013513A1 (fr) 1997-04-17
BR9611007A (pt) 1999-07-13
CY2428B1 (en) 2004-11-12
AU7213296A (en) 1997-04-30

Similar Documents

Publication Publication Date Title
CA2232663C (fr) Antagonistes du recepteur d'at1 destines a prevenir et traiter l'insuffisance renale postischemique et a proteger des reins ischemies
AU2018202986B2 (en) ANG-(1-7) derivative oligopeptides and methods for using and producing the same
VAUGHAN jR et al. Hemodialysis-resistant hypertension: control with an orally active inhibitor of angiotensin-converting enzyme
JPS6197228A (ja) ジヒドロピリジン類とａｃｅ阻害剤との配合物
US20090253665A1 (en) Method of treatment of disease using an adenosine a1 receptor antagonist and an aldosterone inhibitor
JPH0725702B2 (ja) ディルチアゼムおよびアンギオテンシン変換酵素阻害剤を含有する医薬組成物
CA2184712A1 (fr) Traitement de la nephropathie diabetique a l'aide de valsartan
AU2004216133A1 (en) Adenosine A1 receptor antagonist for the treatment of cardiac and renal diseases
EP1146872B1 (fr) Utilisation des antagonistes du recepteur d'angiotensine ii dans le traitement de l'infarctus aigu du myocarde
EP2157089B1 (fr) Utilisations thérapeutiques de dérivés d'acide imidazol-5-carboxylique.
JP2003503457A (ja) 心臓血管合併症の治療用薬剤の製造におけるアンギオテンシンｉｉ１型受容体アンタゴニストの使用
JP4836388B2 (ja) ｅＮＯＳ発現に起因する疾患の予防または治療薬
JPH075482B2 (ja) 腎疾患の治療に有用なアンギオテンシン転換酵素阻害剤
Pritchard et al. Do trandolapril and indomethacin influence renal function and renal functional reserve in hypertensive patients?
KR20130088755A (ko) 서방성 고혈압 및 신 기능 장애 치료제
JPH0119A (ja) 腎機能改善剤
US5747495A (en) Method for treating hypertension using pyrazolopyrimidine derivatives
JPS6379831A (ja) １，４−ジビドロピリジン誘導体およびアシル化１，２，３，４−テトラヒドロイソキノリン−３−カルボン酸を含有する医薬組成物
Imbs et al. Effect of captopril on intrarenal blood flow
US20090118334A1 (en) Method of treatment of cardiac and/or renal failure using a calcium channel blocker and an angiotensin converting enzyme inhibitor or an angiotensin ii receptor blocker
JPH09255589A (ja) ストレス抑制剤
JPWO1992001468A1 (ja) エンドセリン変換酵素阻害剤または血管攣縮治療剤
WO2013073382A1 (fr) Médicament pour le traitement ou la prévention d'une néphropathie

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20130924